These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 23428903

  • 1. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.
    Michels J, Vitale I, Senovilla L, Enot DP, Garcia P, Lissa D, Olaussen KA, Brenner C, Soria JC, Castedo M, Kroemer G.
    Cell Cycle; 2013 Mar 15; 12(6):877-83. PubMed ID: 23428903
    [Abstract] [Full Text] [Related]

  • 2. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
    Olaussen KA, Adam J, Vanhecke E, Vielh P, Pirker R, Friboulet L, Popper H, Robin A, Commo F, Thomale J, Kayitalire L, Filipits M, Le Chevalier T, André F, Brambilla E, Soria JC.
    Lung Cancer; 2013 May 15; 80(2):216-22. PubMed ID: 23410825
    [Abstract] [Full Text] [Related]

  • 3. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
    Cheng H, Zhang Z, Borczuk A, Powell CA, Balajee AS, Lieberman HB, Halmos B.
    Carcinogenesis; 2013 Apr 15; 34(4):739-49. PubMed ID: 23275151
    [Abstract] [Full Text] [Related]

  • 4. Cisplatin resistance associated with PARP hyperactivation.
    Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, Talbot M, Robin A, Girard P, Oréar C, Lissa D, Sukkurwala AQ, Garcia P, Behnam-Motlagh P, Kohno K, Wu GS, Brenner C, Dessen P, Saparbaev M, Soria JC, Castedo M, Kroemer G.
    Cancer Res; 2013 Apr 01; 73(7):2271-80. PubMed ID: 23554447
    [Abstract] [Full Text] [Related]

  • 5. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling.
    Wang LH, Li Y, Yang SN, Wang FY, Hou Y, Cui W, Chen K, Cao Q, Wang S, Zhang TY, Wang ZZ, Xiao W, Yang JY, Wu CF.
    Br J Cancer; 2014 Jan 21; 110(2):341-52. PubMed ID: 24300974
    [Abstract] [Full Text] [Related]

  • 6. Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage.
    Jian W, Xu HG, Chen J, Xu ZX, Levitt JM, Stanley JA, Yang ES, Lerner SP, Sonpavde G.
    Anticancer Drugs; 2014 Sep 21; 25(8):878-86. PubMed ID: 24714082
    [Abstract] [Full Text] [Related]

  • 7. Synergistic effect of arginine-specific ADP-ribosyltransferase 1 and poly(ADP-ribose) polymerase-1 on apoptosis induced by cisplatin in CT26 cells.
    Kuang J, Wang YL, Xiao M, Tang Y, Chen WW, Song GL, Yang X, Li M.
    Oncol Rep; 2014 May 21; 31(5):2335-43. PubMed ID: 24676941
    [Abstract] [Full Text] [Related]

  • 8. PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.
    Jiang Y, Dai H, Li Y, Yin J, Guo S, Lin SY, McGrail DJ.
    Int J Cancer; 2019 Mar 01; 144(5):1092-1103. PubMed ID: 30152517
    [Abstract] [Full Text] [Related]

  • 9. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
    Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, Ator M, Bihovsky R, Hudkins R, Chatterjee S, Klein-Szanto A, Dionne C, Ruggeri B.
    Mol Cancer Ther; 2003 Apr 01; 2(4):371-82. PubMed ID: 12700281
    [Abstract] [Full Text] [Related]

  • 10. An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
    Awada A, Campone M, Varga A, Aftimos P, Frenel JS, Bahleda R, Gombos A, Bourbouloux E, Soria JC.
    Anticancer Drugs; 2016 Apr 01; 27(4):342-8. PubMed ID: 26796987
    [Abstract] [Full Text] [Related]

  • 11. Poly(ADPR)polymerase inhibition and apoptosis induction in cDDP-treated human carcinoma cell lines.
    Gambi N, Tramontano F, Quesada P.
    Biochem Pharmacol; 2008 Jun 15; 75(12):2356-63. PubMed ID: 18468580
    [Abstract] [Full Text] [Related]

  • 12. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
    Paul I, Savage KI, Blayney JK, Lamers E, Gately K, Kerr K, Sheaff M, Arthur K, Richard DJ, Hamilton PW, James JA, O'Byrne KJ, Harkin DP, Quinn JE, Fennell DA.
    J Pathol; 2011 Aug 15; 224(4):564-74. PubMed ID: 21706479
    [Abstract] [Full Text] [Related]

  • 13. A PARP-1/JNK1 cascade participates in the synergistic apoptotic effect of TNFalpha and all-trans retinoic acid in APL cells.
    Mathieu J, Flexor M, Lanotte M, Besançon F.
    Oncogene; 2008 May 29; 27(24):3361-70. PubMed ID: 18084321
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
    Sakogawa K, Aoki Y, Misumi K, Hamai Y, Emi M, Hihara J, Shi L, Kono K, Horikoshi Y, Sun J, Ikura T, Okada M, Tashiro S.
    Cancer Sci; 2013 Dec 29; 104(12):1593-9. PubMed ID: 24033642
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of poly(ADP-ribose) polymerase (PARP) induces apoptosis in lung cancer cell lines.
    Gangopadhyay NN, Luketich JD, Opest A, Visus C, Meyer EM, Landreneau R, Schuchert MJ.
    Cancer Invest; 2011 Nov 29; 29(9):608-16. PubMed ID: 22011283
    [Abstract] [Full Text] [Related]

  • 17. Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induced cisplatin sensitization of non-small cell lung cancer cells.
    Hu Z, Zeng Q, Zhang B, Liu H, Wang W.
    Biochimie; 2014 Dec 29; 107 Pt B():257-62. PubMed ID: 25220870
    [Abstract] [Full Text] [Related]

  • 18. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.
    Postel-Vinay S, Bajrami I, Friboulet L, Elliott R, Fontebasso Y, Dorvault N, Olaussen KA, André F, Soria JC, Lord CJ, Ashworth A.
    Oncogene; 2013 Nov 21; 32(47):5377-87. PubMed ID: 23934192
    [Abstract] [Full Text] [Related]

  • 19. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
    Deben C, Wouters A, Op de Beeck K, van Den Bossche J, Jacobs J, Zwaenepoel K, Peeters M, Van Meerbeeck J, Lardon F, Rolfo C, Deschoolmeester V, Pauwels P.
    Oncotarget; 2015 Sep 08; 6(26):22666-79. PubMed ID: 26125230
    [Abstract] [Full Text] [Related]

  • 20. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.
    Ui T, Morishima K, Saito S, Sakuma Y, Fujii H, Hosoya Y, Ishikawa S, Aburatani H, Fukayama M, Niki T, Yasuda Y.
    Oncol Rep; 2014 Feb 08; 31(2):619-24. PubMed ID: 24317439
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.